spantide II

tachykinin antagonist

Also Known As:

1-NicLys-3-(3-Pal)-5-Cl2Phe-6-Asn-7,9-Trp-11-Nle-substance P; 1-nicotinyl-lysyl-3-pyridyl-alanyl-5-dichloro-phenylalanyl-6-asparaginyl-7,9-tryptophyl-11-norleucine-substance P; NPCATN-SP; substance P, Nic-Lys(1)-3-Pal(3)-Cl2-Phe(5)-Asn(6)-Trp(7,9)-Nle(11)-; substance P, nicotinyllysyl(1)-3-pyridylalanyl(3)-dichlorophenyl(5)-asparaginyl(6)-tryptophyl(7,9)-norleucine-; L-Norleucinamide, N6-(3-pyridinylcarbonyl)-D-lysyl-L-prolyl-3-(3-pyridinyl)-L-alanyl-L-prolyl-3,4-dichloro-D-phenylalanyl-L-asparaginyl-D-tryptophyl-L-phenylalanyl-D-tryptophyl-L-leucyl-

Networked: 8 relevant articles (1 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Kikwai, Loice: 3 articles (10/2005 - 01/2004)
2.	Singh, Mandip: 3 articles (10/2005 - 01/2004)
3.	Matsui, Hidenori: 2 articles (01/2020 - 10/2017)
4.	Murayama, Somay Y: 2 articles (01/2020 - 10/2017)
5.	Nakamura, Masahiko: 2 articles (01/2020 - 10/2017)
6.	Takahashi, Shinichi: 2 articles (01/2020 - 10/2017)
7.	Ansel, John C: 2 articles (10/2005 - 01/2004)
8.	Armstrong, Cheryl A: 2 articles (10/2005 - 01/2004)
9.	Babu, R Jayachandra: 2 articles (10/2005 - 01/2004)
10.	Kanikkannan, Narayanasamy: 2 articles (01/2004 - 01/2004)

Related Diseases

1.	Neoplasms (Cancer) 01/01/2020 - "Substance P immunoreactivity was clearly shown in the lymphoma cells in the liver and lung, and the spantide II administration induced the marked decrease in the size of tumors. "
2.	Lymphoma (Lymphomas) 01/01/2020 - "Substance P immunoreactivity was clearly shown in the lymphoma cells in the liver and lung, and the spantide II administration induced the marked decrease in the size of tumors. "
3.	Allergic Contact Dermatitis 10/31/2005 - "The in vivo anti-inflammatory activity of Spantide II formulations was evaluated in an allergic contact dermatitis (ACD) mouse model. " 01/01/2004 - "Spantide II is a peptide with a molecular weight of 1670.2 which binds to neurokinin-1 receptor (NKR-1) and blocks proinflammatory activities associated with SP. The aim of this study was to investigate in vitro permeation and distribution of spantide II through hairless rat skin and the anti-inflammatory effect of topically delivered spantide II in an allergic contact dermatitis (ACD) mouse model. "
4.	Inflammation (Inflammations) 01/01/2004 - "The current study demonstrates that spantide II can effectively be delivered to epidermis and dermis to exert a significant anti-inflammatory activity on the reduction of inflammation in a mouse model of ACD." 01/01/2004 - "Spantide II is a peptide (MW 1668.76) that specifically binds to neurokinin-1 receptor (NKR-1) and blocks inflammation associated with substance P. "
5.	Marginal Zone B-Cell Lymphoma (MALT Lymphoma) 10/30/2017 - "To the MALT lymphoma study, the distribution of the substance P and effect of substance P antagonist, spantide II, was investigated by immunohistochemical studies. "

Related Drugs and Biologics

1.	Substance P
2.	Peptides (Polypeptides)
3.	Neurokinin-1 Receptors (Neurokinin 1 Receptor)
4.	6-Cyano-7-nitroquinoxaline-2,3-dione (6 Cyano 7 nitroquinoxaline 2,3 dione)
5.	alpha- Amino- 3- hydroxy- 5- methyl- 4- isoxazolepropionic Acid (AMPA)
6.	Kainic Acid Receptors (Kainate Receptor)
7.	Dizocilpine Maleate (Dizocilpine)
8.	N-Methyl-D-Aspartate Receptors (NMDA Receptors)
9.	Tachykinins
10.	Anti-Inflammatory Agents (Anti-Inflammatories)